{"id":"emylcamate","rwe":[{"pmid":"4860508","year":"1967","title":"Long-term treatment of alcoholism with amitriptyline and emylcamate. A double-blind evaluation.","finding":"","journal":"Quarterly journal of studies on alcohol","studyType":"Clinical Study"},{"pmid":"14052966","year":"1963","title":"[THE ORTHONEUROTIC EMYLCAMATE IN DAILY PRACTICE].","finding":"","journal":"Bruxelles medical","studyType":"Clinical Study"},{"pmid":"14074232","year":"1963","title":"A STUDY OF A NEW TRANQUILIZER IN GENERAL PRACTICE: EMYLCAMATE IN 400 PATIENTS.","finding":"","journal":"Current therapeutic research, clinical and experimental","studyType":"Clinical Study"},{"pmid":"13966735","year":"1962","title":"[Effect of meprobamate and emylcamate on human performance in a prolonged serial task].","finding":"","journal":"Psychopharmacologia","studyType":"Clinical Study"},{"pmid":"13876949","year":"1962","title":"Emylcamate in hospitalized mentally retarded spastic patients.","finding":"","journal":"Diseases of the nervous system","studyType":"Clinical Study"}],"tags":[{"label":"emylcamate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N05BC03","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"diethyl methyl carbinol urethan","offLabel":[],"synonyms":["emylcamate","3-Methyl-3-pentanol carbamate","diethyl methyl carbinol urethan"],"timeline":[],"approvals":[],"brandName":"Diethyl Methyl Carbinol Urethan","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"emylcamate","explanation":"Imagine your body's cells are like locks, and the target is the key that fits into those locks. When EMYLCAMATE binds to the target, it can affect how the cells work, potentially leading to changes in the body's chemistry. However, the exact way it works is still a mystery.","oneSentence":"EMYLCAMATE is thought to work by interacting with a specific target in the body, although the exact mechanism is not well understood.","technicalDetail":"As a small molecule, EMYLCAMATE is likely to exert its effects by binding to a specific protein or receptor, potentially altering its activity or expression. Further research is needed to determine the precise molecular mechanisms underlying its action."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1004","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EMYLCAMATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:55:23.339038","biosimilars":[],"competitors":[{"drugName":"meprobamate","drugSlug":"meprobamate","fdaApproval":"1955-04-28","genericCount":28,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mebutamate","drugSlug":"mebutamate","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"emylcamate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"meprobamate","brandName":"meprobamate","genericName":"meprobamate","approvalYear":"1955","relationship":"same-class"},{"drugId":"mebutamate","brandName":"mebutamate","genericName":"mebutamate","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"KCJ747D3R4","CHEBI":"CHEBI:134769","INN_ID":"888","UMLSCUI":"C0175159","ChEMBL_ID":"CHEMBL2104208","KEGG_DRUG":"D07317","DRUGBANK_ID":"DB13572","PUBCHEM_CID":"6526","SNOMEDCT_US":"73076001","MESH_SUPPLEMENTAL_RECORD_UI":"C100111"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":10,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"N05BC03","allCodes":["N05BC03"]},"biosimilarFilings":[],"recentPublications":[{"date":"1967 Jun","pmid":"4860508","title":"Long-term treatment of alcoholism with amitriptyline and emylcamate. A double-blind evaluation.","journal":"Quarterly journal of studies on alcohol"},{"date":"1963 Oct 6","pmid":"14052966","title":"[THE ORTHONEUROTIC EMYLCAMATE IN DAILY PRACTICE].","journal":"Bruxelles medical"},{"date":"1963 Oct","pmid":"14074232","title":"A STUDY OF A NEW TRANQUILIZER IN GENERAL PRACTICE: EMYLCAMATE IN 400 PATIENTS.","journal":"Current therapeutic research, clinical and experimental"},{"date":"1962 Oct 5","pmid":"13966735","title":"[Effect of meprobamate and emylcamate on human performance in a prolonged serial task].","journal":"Psychopharmacologia"},{"date":"1962 Apr","pmid":"13876949","title":"Emylcamate in hospitalized mentally retarded spastic patients.","journal":"Diseases of the nervous system"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Diethyl Methyl Carbinol Urethan (EMYLCAMATE) is a small molecule drug in the emylcamate class, but its target and approved indications are unknown. Its commercial status, including patent status and generic manufacturers, is also unclear. As a result, key safety considerations and pharmacokinetic properties such as half-life and bioavailability are not well established. Further research is needed to understand the potential benefits and risks of this compound. Its current owner is also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}